Preclinical biodistribution and safety evaluation of Olig001-AAV-mediated ARSA gene delivery following intrathecal administration in a porcine model
Life Research · 2026 · 9 (4) · 22
DOI: 10.53388/lr20260022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Research, 2026. Verfasst von Aysilu Ayupova und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Metachromatic leukodystrophy is a severe lysosomal storage disorder caused by a deficiency of arylsulfatase A (ARSA), resulting in progressive demyelination affecting both the central and peripheral nervous systems. Achieving efficient therapeutic gene delivery to the central nervous system (CNS) remains a major obstacle in the development of effective treatments. AAV-Olig001 is an oligodendrocyte-targeting viral vector with the potential to enhance ARSA gene delivery following intrathecal administration.
Methods
The functionality of AAV-Olig001-ARSA was evaluated through in vitro transduction of HEK293T cells and intrathecal administration in mannitol-pretreated pigs. ARSA mRNA and protein expression were analyzed by qPCR, Western blotting, enzymatic activity assays, and immunofluorescence. Treatment safety was assessed using hematological and serum biochemical analyses.
Results
AAV-Olig001-ARSA produced marked ARSA overexpression in vitro. In the porcine model, transgene mRNA was detected in multiple CNS regions and was accompanied by increased ARSA enzymatic activity. Immunofluorescence demonstrated enhanced ARSA expression in Purkinje cells, cortical neurons, and dorsal root ganglia. Biochemical markers remained within normal ranges.
Conclusion
Intrathecal administration of AAV-Olig001-ARSA resulted in transgene expression across multiple regions of the CNS and increased functional ARSA activity in a large-animal model. The treatment was generally well tolerated, although transient hematological alterations suggestive of an immune response were observed. Overall, these findings highlight the therapeutic potential of AAV-Olig001 for metachromatic leukodystrophy. However, additional long-term preclinical studies involving larger cohorts are required to address the observed immunogenicity and the current study limitations, including the limited sample size, short observation period, and absence of functional outcome measures, before clinical translation can be considered.
Zitieren
APA
Ayupova, A., Ibrahim, A., Fattakhova, A., Sharshakova, A., Solovyeva, V., Mukhamedshina, Y., Sabirov, D., & Rizvanov, A. (2026). Preclinical biodistribution and safety evaluation of Olig001-AAV-mediated ARSA gene delivery following intrathecal administration in a porcine model. Life Research, 9(4), 22. https://doi.org/10.53388/lr20260022
Vancouver
Ayupova A, Ibrahim A, Fattakhova A, Sharshakova A, Solovyeva V, Mukhamedshina Y, et al. Preclinical biodistribution and safety evaluation of Olig001-AAV-mediated ARSA gene delivery following intrathecal administration in a porcine model. Life Research. 2026;9(4):22. doi:10.53388/lr20260022
BibTeX
@article{Ayupova2026,
author = {Ayupova, Aysilu and Ibrahim, Ahmad and Fattakhova, Alisa and Sharshakova, Alexandra and Solovyeva, Valeria and Mukhamedshina, Yana and Sabirov, Davran and Rizvanov, Albert},
title = {Preclinical biodistribution and safety evaluation of Olig001-AAV-mediated ARSA gene delivery following intrathecal administration in a porcine model},
journal = {Life Research},
year = {2026},
volume = {9},
number = {4},
pages = {22},
doi = {10.53388/lr20260022}
}
EUVIMED